Summary
For Year 2026-27, Brawn Biotech reports the following shareholding: Total Promoters at 53.39%, Mutual Fund at 0.35%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 46.26%. This breakdown provides a quick snapshot of ownership distribution for Brawn Biotech in 2026-27.
Brawn Biotech FAQs
As of 04-2026, the promoter shareholding in Brawn Biotech stands at 53.39% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Brawn Biotech is 0% and 0% respectively.
The retail shareholding of the Brawn Biotech is 46.26%.
Changes in shareholding patterns of Brawn Biotech can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Brawn Biotech are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
